EFFICACY AND SAFETY OF CRISABOROLE IN PATIENTS ≥3 MONTHS OF AGE WITH MILD-TO-MODERATE ATOPIC DERMATITIS (AD)

被引：0
|
作者：
Su, John C. [1 ]
Spelman, Lynda J. [2 ]
Eichenfield, Lawrence F. [3 ,4 ]
Gold, Linda F. Stein [5 ]
Cha, Amy [6 ]
Graham, Daniela [7 ]
Takiya, Liza [8 ]
Werth, John L. [9 ]
Zang, Chuanbo [10 ]
Vlahos, Bonnie [11 ]
机构：
[1] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia
[2] Verac Clin Res, Brisbane, Qld, Australia
[3] Univ Calif San Diego, Rady Childrens Hosp San Diego, Pediat & Adolescent Dermatol, San Diego, CA USA
[4] Univ Calif San Diego, Dept Dermatol & Pediat, San Diego, CA USA
[5] Henry Ford Hlth Syst, Dept Dermatol, Detroit, MI USA
[6] Pfizer Inc, Global Med Affairs Inflammat & Immunol, New York, NY USA
[7] Pfizer Inc, Hlth Econ & Outcomes Res Patient & Hlth Impact In, Collegeville, PA USA
[8] Pfizer Inc, North Amer Med Affairs Inflammat & Immunol, Collegeville, PA USA
[9] Pfizer Inc, Clin Dev & Operat, Collegeville, PA USA
[10] Pfizer Inc, Biostat, Collegeville, PA USA
[11] Pfizer Inc, Global Prod Dev Inflammat & Immunol, Collegeville, PA USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
PT12
引用
收藏
页码：55 / 56
页数：2
相关论文
共 50 条
  • [41] Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis
    Seghers A.C.
    Cai S.C.
    Ho M.S.L.
    Giam Y.C.
    Tan L.
    Grönhagen C.M.
    Tang M.B.Y.
    Dermatology and Therapy, 2014, 4 (1) : 83 - 92
  • [42] Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
    Luger, Thomas A.
    Hebert, Adelaide A.
    Zaenglein, Andrea L.
    Silverberg, Jonathan, I
    Tan, Huaming
    Ports, William C.
    Zielinski, Michael A.
    PEDIATRIC DRUGS, 2022, 24 (02) : 175 - 183
  • [43] Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
    Eric L. Simpson
    Amy S. Paller
    Mark Boguniewicz
    Lawrence F. Eichenfield
    Steven R. Feldman
    Jonathan I. Silverberg
    Sarah L. Chamlin
    Lee T. Zane
    Dermatology and Therapy, 2018, 8 : 605 - 619
  • [44] Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
    Simpson, Eric L.
    Paller, Amy S.
    Boguniewicz, Mark
    Eichenfield, Lawrence F.
    Feldman, Steven R.
    Silverberg, Jonathan I.
    Chamlin, Sarah L.
    Zane, Lee T.
    DERMATOLOGY AND THERAPY, 2018, 8 (04) : 605 - 619
  • [45] Efficacy and safety of B244, a live topical biotherapeutic, in patients with pruritus associated with mild-to-moderate atopic dermatitis
    Kim, Hyun
    Gryllos, Ioannis
    Li, Connie
    Brownell, Daniel
    Krueger, Todd
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E133 - E133
  • [46] Improvement in Disease Severity and Pruritus Outcomes With Crisaborole Ointment, 2%, by Baseline Atopic Dermatitis Severity in Children and Adolescents With Mild-to-Moderate Atopic Dermatitis
    Eichenfield, L. F.
    Yosipovitch, G.
    Gold, Stein L. F.
    PEDIATRICS, 2021, 148 : S18 - S19
  • [47] Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis
    Eichenfield, Lawrence F.
    Yosipovitch, Gil
    Stein Gold, Linda F.
    Kalabis, Mizuho
    Zang, Chuanbo
    Vlahos, Bonnie
    Sanders, Paul
    Myers, Daniela E.
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Olivadoti, Melissa
    Paller, Amy S.
    PEDIATRIC DERMATOLOGY, 2020, 37 (06) : 1030 - 1037
  • [48] Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
    Fahrbach, Kyle
    Tarpey, Jialu
    Washington, Evelien Bergrath
    Hughes, Rachel
    Thom, Howard
    Neary, Maureen P.
    Cha, Amy
    Gerber, Robert
    Cappelleri, Joseph C.
    DERMATOLOGY AND THERAPY, 2020, 10 (04) : 681 - 694
  • [49] Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
    Kyle Fahrbach
    Jialu Tarpey
    Evelien Bergrath Washington
    Rachel Hughes
    Howard Thom
    Maureen P. Neary
    Amy Cha
    Robert Gerber
    Joseph C. Cappelleri
    Dermatology and Therapy, 2020, 10 : 681 - 694
  • [50] A clinical study on the efficacy and safety of the exopolymers from Aureobasidium pullulans (EAP) in subjects with mild-to-moderate atopic dermatitis
    Park, Hye-Su
    Kang, Minseo
    Kim, Yong-Min
    Lim, Jong-Min
    Kim, Young Suk
    Kim, Hee-Taek
    Choi, Jae-Suk
    TOXICOLOGY AND ENVIRONMENTAL HEALTH SCIENCES, 2020, 12 (01) : 31 - 43
12345